Last updated on July 2018

A Randomized, Double-Blind, Parallel Group, Multi-Center 12-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo in Subjects With Persistent Asthma


Brief description of study

To assess the effect of 3 doses of GP MDI compared to Placebo MDI and Spiriva® Respimat® on lung function over 24 weeks in subjects with persistent asthma. 

Clinical Study Identifier: TX155589

Contact Investigators or Research Sites near you

Start Over

Columbus Regional Research Institute

IACT Health
Columbus, GA United States
  Connect »